Claritin OTC Switch In Pediatric Populations Could Pose Concerns For NDAC
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members may be hesitant to favor an Rx-to-OTC switch of Schering-Plough's Claritin franchise for younger pediatric patients
You may also be interested in...
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC